Abbott Laboratories vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Abbott Laboratories trades at $109.6 (market cap $187.95B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.91. The key difference: Abbott Laboratories pays a 2.32% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | PDBC | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $18.91 |
52-Week Low | $82.57 | $12.90 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
PDBC trades at $17.87, up 0.22% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on diversified commodities, avoiding K-1 tax forms, and has seen strong institutional inflows, including a 150.6% position increase by Geneos Wealth Management in Q1 2026 (SEC filing, 2026-07-19). Recent news highlights commodities' role as an inflation hedge, with PDBC returning 37% since March 2024, though momentum has weakened recently (Seeking Alpha, 2026-06-11).
The outlook for PDBC is supported by geopolitical tensions and inflation hedging demand, but risks include commodity price volatility and Middle East conflicts. Wall Street sentiment is mixed, with a recent downgrade to hold due to fading momentum, yet institutional interest remains strong, indicating long-term confidence in commodities exposure.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →